Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Barlaam · SciRah

Researcher profile · Semantic Scholar

B. Barlaam

Share profile

B. Barlaam — researcher profile on SciRah

h-index: 22
Works: 88
Citations: 1,732

Most-cited papers

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches, A. G. Trinidad, Gareth D. Hughes, Gemma N. Jones +17 more
2019Molecular Cancer Therapeutics136 citations
Semantic Scholar
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
D. Hickinson, T. Klinowska, G. Speake, J. Vincent +12 more
2010Clinical Cancer Research121 citations Open access
Semantic Scholar
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
K. Pike, B. Barlaam, E. Cadogan, Andrew Campbell +24 more
2018Journal of Medicinal Chemistry105 citations Open access
Semantic Scholar
Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist.
James S. Scott, T. Moss, Amber Y. S. Balazs, B. Barlaam +42 more
2020Journal of Medicinal Chemistry103 citations Open access
Semantic Scholar
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
B. Barlaam, R. Casella, Justin Cidado, C. Cook +37 more
2020Journal of Medicinal Chemistry91 citations Open access
Semantic Scholar
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs J Hancox, S. Cosulich, Lyndsey Hanson, C. Trigwell +20 more
2014Molecular Cancer Therapeutics83 citations Open access
Semantic Scholar
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
B. Barlaam, T. G. Bird, Christine Lambert-van der Brempt, D. Campbell +2 more
1999Journal of Medicinal Chemistry82 citations Open access
Semantic Scholar
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.
B. Barlaam, S. Cosulich, S. Degorce, M. Fitzek +14 more
2015Journal of Medicinal Chemistry79 citations Open access
Semantic Scholar
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
S. Degorce, B. Barlaam, E. Cadogan, A. Dishington +10 more
2016Journal of Medicinal Chemistry69 citations Open access
Semantic Scholar
Targeting the kinase activities of ATR and ATM exhibits therapeutic potential in a mouse model of MLL-rearranged AML
Isabel Morgado-Palacin, Amanda M. Day, M. Murga, V. Lafarga +15 more
2016Science Signaling63 citations Open access
Semantic Scholar
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.
J. Johannes, L. Almeida, B. Barlaam, P. Boriack-Sjodin +26 more
2015ACS Medicinal Chemistry Letters58 citations Open access
Semantic Scholar
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
R. Ducray, P. Ballard, B. Barlaam, M. Hickinson +3 more
2008Bioorganic & Medicinal Chemistry Letters58 citations Open access
Semantic Scholar
Orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice
Jeremy Karlin, Jasmine Allen, S. F. Ahmad, Gareth D. Hughes +32 more
2018Molecular Cancer Therapeutics47 citations Open access
Semantic Scholar
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
B. Barlaam, S. Cosulich, Bénédicte Delouvrié, Rebecca P A Ellston +20 more
2015Bioorganic & Medicinal Chemistry Letters41 citations
Semantic Scholar
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
B. Barlaam, J. Anderton, P. Ballard, R. Bradbury +9 more
2013ACS Medicinal Chemistry Letters39 citations Open access
Semantic Scholar
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
B. Barlaam, E. Cadogan, Andrew Campbell, N. Colclough +16 more
2018ACS Medicinal Chemistry Letters28 citations Open access
Semantic Scholar
Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
B. Barlaam, R. Ducray, Christine Lambert-van der Brempt, P. Plé +6 more
2011Bioorganic & Medicinal Chemistry Letters28 citations Open access
Semantic Scholar
Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.
F. Giordanetto, B. Barlaam, Susanne Berglund, K. Edman +4 more
2014Bioorganic & Medicinal Chemistry Letters26 citations Open access
Semantic Scholar
Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.
C. Bardelle, B. Barlaam, N. Brooks, T. Coleman +6 more
2010Bioorganic & Medicinal Chemistry Letters26 citations Open access
Semantic Scholar
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
P. Ballard, B. Barlaam, R. Bradbury, A. Dishington +13 more
2007Bioorganic & Medicinal Chemistry Letters23 citations Open access
Semantic Scholar
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
B. Barlaam, C. De Savi, A. Dishington, L. Drew +25 more
2021Journal of Medicinal Chemistry22 citations Open access
Semantic Scholar
New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors.
B. Barlaam, M. Fennell, Hervé Germain, T. Green +6 more
2005Bioorganic & Medicinal Chemistry Letters22 citations Open access
Semantic Scholar
New hydroxylamines for the synthesis of hydroxamic acids
B. Barlaam, A. Hamon, M. Maudet
199822 citations
Semantic Scholar
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.
James M. Smith, B. Barlaam, David Beattie, Lauren Bradshaw +38 more
2024Journal of Medicinal Chemistry20 citations Open access
Semantic Scholar
Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
B. Barlaam, S. Cosulich, S. Degorce, M. Fitzek +11 more
2014Bioorganic & Medicinal Chemistry Letters19 citations Open access
Semantic Scholar
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
K. Pike, T. Hunt, B. Barlaam, David Benstead +22 more
2024Journal of Medicinal Chemistry17 citations Open access
Semantic Scholar
Solid-phase synthesis of hydroxamic acid based TNF-α convertase inhibitors☆
B. Barlaam, P. Koza, J. Berriot
199917 citations
Semantic Scholar
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)
James S. Scott, B. Barlaam
2021Expert Opinion on Therapeutic Patents16 citations
Semantic Scholar
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
B. Barlaam, P. Ballard, R. Bradbury, R. Ducray +15 more
2008Bioorganic & Medicinal Chemistry Letters16 citations Open access
Semantic Scholar
Novel 3‐Alkoxy‐1H‐pyrazolo[3,4‐d]pyrimidines as EGFR and erbB2 Receptor Tyrosine Kinase Inhibitors.
R. Ducray, P. Ballard, B. Barlaam, M. Hickinson +3 more
200816 citations
Semantic Scholar
Inhibitors of the Tyrosine Kinase EphB4. Part 3. Identification of Non-benzodioxole-Based Kinase Inhibitors.
C. Bardelle, B. Barlaam, N. Brooks, T. Coleman +6 more
201115 citations
Semantic Scholar
Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833.
James S. Scott, T. Moss, B. Barlaam, Paul R. J. Davey +11 more
2020ACS Medicinal Chemistry Letters14 citations Open access
Semantic Scholar
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
James S. Scott, D. Stead, B. Barlaam, J. Breed +39 more
2023Journal of Medicinal Chemistry13 citations
Semantic Scholar
Insight into the complexation mode of bis(nitrilotriacetic acid) (NTA) ligands with Ni(2+) involved in the labeling of histidine-tagged proteins.
Marie Brellier, B. Barlaam, C. Mioskowski, Rachid Baati
2009Chemistry13 citations
Semantic Scholar
An expedient total synthesis of (±)-estrone derivatives
B. Barlaam, J. Boivin, L. El Kaim, S. Zard
199113 citations
Semantic Scholar
A short total synthesis of estrone derivatives: A novel 1,3-rearrangement of an allylic nitro group
B. Barlaam, J. Boivin, Laurent Elkaim, Sarah Elton-Farr +1 more
199512 citations
Semantic Scholar
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome.
Avipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, Amber Y. S. Balazs +54 more
2025Journal of Medicinal Chemistry11 citations
Semantic Scholar
Identifying high quality, potent and selective inhibitors of ATM kinase: Discovery of AZD0156
B. Barlaam, K. Pike
201611 citations
Semantic Scholar
Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.
B. Barlaam, S. Cosulich, M. Fitzek, S. Green +8 more
2015Bioorganic & Medicinal Chemistry Letters11 citations Open access
Semantic Scholar
Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors.
N. Grimster, L. Gingipalli, B. Barlaam, Qibin Su +29 more
2009Bioorganic & Medicinal Chemistry Letters11 citations
Semantic Scholar
Use of Direct-to-Biology Strategies for the Discovery of 2'-Deoxynucleoside 5'-Monophosphate N-Glycosidase (DNPH1) PROTACs.
Niall A Anderson, B. Barlaam, A. Argyrou, Peter C Astles +26 more
2025Journal of Medicinal Chemistry10 citations
Semantic Scholar
Synthesis of Novel Hydroxymethyl-Substituted Fused Heterocycles
Jane L. Holmes, T. McGuire, L. Almeida, B. Barlaam +15 more
2016Synthesis9 citations
Semantic Scholar
A new synthesis of substituted dienes by reductive elimination of allylic nitro derivatives
B. Barlaam, J. Boivin, S. Zard
19939 citations
Semantic Scholar
A practical access to allylic sulphones and lactones from allylic nitro compounds
B. Barlaam, J. Boivin, S. Zard
19909 citations
Semantic Scholar
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
B. Barlaam, S. Cosulich, M. Fitzek, Hervé Germain +13 more
2017Bioorganic & Medicinal Chemistry Letters8 citations Open access
Semantic Scholar
Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods.
J. A. Hendricks, N. Beaton, Alexey L. Chernobrovkin, Eric Miele +18 more
2021ACS Chemical Biology7 citations Open access
Semantic Scholar
Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
B. Barlaam, S. Cosulich, S. Degorce, M. Fitzek +11 more
2016Bioorganic & Medicinal Chemistry Letters7 citations Open access
Semantic Scholar
General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles
Jeffrey Varnes, T. McGuire, R. Meadows, B. Barlaam +24 more
20167 citations
Semantic Scholar
Two-Directional Approach for the Rapid Synthesis of 2,4-Bis-Aminoaryl Pyridine Derivatives
R. Morgentin, B. Barlaam, K. Foote, L. Hassall +5 more
20127 citations
Semantic Scholar
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
B. Barlaam, S. Cosulich, S. Degorce, Rebecca P A Ellston +10 more
2017Bioorganic & Medicinal Chemistry Letters5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Pike×13
Invite
K. Pike — researcher profile on SciRah
Christine Lambert-van der Brempt×10
Invite
Christine Lambert-van der Brempt — researcher profile on SciRah
A. Dishington×9
Invite
A. Dishington — researcher profile on SciRah
T. McGuire×9
Invite
T. McGuire — researcher profile on SciRah

Invite

R. Ducray — researcher profile on SciRah

Invite

S. Cosulich — researcher profile on SciRah

Invite

M. Fitzek — researcher profile on SciRah

Invite

L. Ward — researcher profile on SciRah

Invite

S. Green — researcher profile on SciRah

Invite

E. Cadogan — researcher profile on SciRah

Invite

D. Ogilvie — researcher profile on SciRah

Invite

S. Degorce — researcher profile on SciRah